$ADTX Cashflow Statement | Understand Stock

$ADTX

$0.01 +$0.00 (0.0%) Close

$ADTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation
Stock-based compensation from asset purchase
Depreciation expense
Amortization of intangible assets
Amortization of debt discount
Amortization of debt discount - note payable
Amortization of debt discount - note receivable
Loss on note exchange agreement
Modifications of warrants as debt issuance costs
Modification of warrants for debt issuance costs
New principal from extension of notes, net of debt discount
Change in fair value of derivative liability
Change in fair value of Evofem warrants
Impairment of Evofem F-1 preferred stock
Disposal of fixed assets
Gain on note exchange agreement
Impairment on notes receivable
Bargain purchase gain from purchase of Evofem convertible notes
Impairment of fixed assets

Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses
Deposits
Inventory
Accounts payable and accrued expenses
Settlement liability
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Notes receivable and accrued interest
Purchase of fixed assets
Tenant improvement allowance receivable
Investment in convertible notes receivable and warrants
Investment in Evofem F-1 preferred stock
Net cash used in investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from note payable - related party
Proceeds from notes payable, related party
Proceeds from notes and convertible notes payable, net of offering costs
Repayments of note payable - related party
Sale of Series B Preferred shares to related party
Redemption of Series B Preferred shares to related party
Repayments of note payable
Sale of Preferred shares to related party
Redemption of Preferred shares to related party
Common stock, preferred stock, and warrants issued for cash, net of issuance costs
Sale of Series C Preferred shares, related party
Redemption of Series C Preferred shares, related party
Cash from subscription receivable
Payments on financing on fixed asset
Cash paid on extinguishment of note payable
Proceeds from exercises of warrants
Redemptions of A-1 preferred stock
Redemptions of C-1 preferred stock
Redemptions of D-1 preferred stock
Net cash provided by financing activities
NET DECREASE IN CASH

NET INCREASE IN CASH
CASH AT BEGINNING OF PERIOD
CASH AT END OF PERIOD
Common stock and warrants issued for cash, net of issuance costs
Supplemental cash flow information:
Cash paid for interest expense
Cash paid for interest

NONCASH INVESTING AND FINANCING ACTIVITIES:
Issuance of shares for the settlement of notes payable
Lease liability recognized from right of use asset
Issuance of shares for the conversion of notes payable
Shares issued for debt offering costs
Debt discount from shares issued as inducement for note payable
Warrant modification
Issuance of shares in asset purchase
Shares issued for settlement
Original offering discount on convertible note payable
Debt discount from warrants issued with convertible note payable
Debt discount from warrant consideration for convertible debt offering costs
Debt discount from shares issued as inducement for convertible note payable
Liability recognized for financed assets
Reduction in exercise price of warrants
Return of notes payable from Evofem merger agreement
Deferred issuance costs
Issuance of shares of Pearsanta Common Stock for IP
Assumption of notes payable from Evofem merger agreement
Series A-1 Preferred shares issued for exchange agreement
Accrued intertest rolled into notes payable
Series B-2 Preferred shares issued in note exchange agreement
Accrued interest rolled into notes payable
Settlement of liability for Series C-1 Convertible Preferred Stock
Exchange of warrants for Series C-1 convertible preferred stock
Derivative liability from conversion feature on preferred stock
ELOC payable
Series C-1 redemption payable
ELOC commitment fee stock payable
Loan in escrow
Reclassification of series A-1 preferred shares to liabilities
Write off of financed asset
Initial recognition of lease liability and right of use asset

Comments